Related Experiment Video

Updated: Aug 16, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Palivizumab for preterm infants. Is it worth it?

N D Embleton1, C Harkensee, M C Mckean

  • 1Newcastle Neonatal Service, Department of Child Health, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK. n.d.embleton@ncl.ac.uk

Archives of Disease in Childhood. Fetal and Neonatal Edition
|July 23, 2005
PubMed

Insights

Palivizumab prophylaxis for respiratory syncytial virus (RSV) in preterm infants shows limited benefits, with no proven cost-effectiveness in the UK. Further economic assessment is needed for high-risk infants.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Health Economics

Background:

  • Respiratory syncytial virus (RSV) infection causes significant infant morbidity.
  • Palivizumab prophylaxis is a common intervention, but its cost-effectiveness is debated.
  • Preterm infants are a high-risk group for severe RSV outcomes.

Purpose of the Study:

  • To systematically review the safety, efficacy, and cost-effectiveness of palivizumab prophylaxis for preterm infants in the UK.
  • To evaluate the economic justification for current palivizumab usage.
  • To inform clinical and policy decisions regarding RSV prevention.

Main Methods:

  • Systematic literature search for randomized controlled trials and economic studies.
  • Focused on palivizumab prophylaxis in preterm infants within the United Kingdom.
  • Analysis of safety, efficacy (hospital admissions, serious outcomes), and cost-effectiveness data.

Main Results:

  • One randomized controlled trial showed reduced hospital admissions but no improvement in severe outcomes.
  • No UK-based cost studies demonstrated economic benefit for palivizumab prophylaxis.
  • Evidence suggests limited overall benefit relative to cost.

Conclusions:

  • Current evidence does not strongly support the cost-effectiveness of palivizumab prophylaxis for preterm infants in the UK.
  • While potentially justifiable for high-risk infants, a comprehensive economic assessment is lacking.
  • The high cost of new treatments necessitates rigorous economic evaluation.

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: